Comunicati Stampa
Editoria e Media

Study Published in British Journal of Cancer Shows High Sensitivity and Specificity of Tethis' Liquid Biopsy Platform in Early Stage Breast Cancer and The Identification of Circulating Tumor Cells Clusters for the First Time in Non-Metastatic…

"My team and I have been working on CTC clusters and their role in the metastatic process for years," said Prof. Nicola Aceto, Ph.D., Professor of Molecular Oncology and Group Leader at the Swiss Federal Institute of Technology (ETH) Zurich. "To find them in a significant proportion of patients with localized cancer is groundbreaking, and although the study is small, it paves the way for larger trials to assess their clinical significance and evaluate the efficacy of anti CTC-clusters therapeutics currently in development."
MILAN, (informazione.news - comunicati stampa - editoria e media)

"My team and I have been working on CTC clusters and their role in the metastatic process for years," said Prof. Nicola Aceto , Ph.D., Professor of Molecular Oncology and Group Leader at the Swiss Federal Institute of Technology (ETH) Zurich . "To find them in a significant proportion of patients with localized cancer is groundbreaking, and although the study is small, it paves the way for larger trials to assess their clinical significance and evaluate the efficacy of anti CTC-clusters therapeutics currently in development."

"We are thrilled about the results of this study," said Roberta Carbone , Ph.D., Chief Scientific Officer at Tethis "which strongly suggests the feasibility of a non-invasive test for early breast cancer detection based on our proprietary liquid biopsy platform. We strongly believe that immediate, standardized and gentle blood sample preparation are the key drivers for success in a difficult setting such as early cancer detection, and that our platform properly addresses these needs."

Tethis S.p.A is based in Milan, Italy , and is developing a novel workflow to bring liquid biopsy in the clinical practice for the precise management of cancer. Tethis' technology points to standardization of the blood sample preparation to provide the highest quality and integrity of liquid biopsy specimens for the comprehensive analysis of clinically informative biomarkers. The company's proprietary nanocoated slides combined with the automated pre-analytical instrument allow to identify and characterize rare cells in blood, like circulating tumor cells, with unprecedented sensitivity, also in early stage settings.

Further information is available on the company's website, www.tethis-lab.com.

Logo - https://mma.prnewswire.com/media/1473369/Tethis_Logo.jpg  

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili